Articles
Perspectives from our scientists.
· Camila Guerrero De Blois, PhD
Computational biology as risk reduction in pharma R&D: an interview with Danuta Gawel
Why programs still reach Phase II on limited evidence, and four things R&D leaders can change on Monday.
· Camila Guerrero De Blois, PhD
Curated vs Data-Derived Evidence in AI Drug Discovery
AI drug discovery tools claim to show their evidence, but from where? Compare curated knowledge with data-derived evidence and why the source matters
· Camila Guerrero De Blois, PhD
Beyond differential expression: How gene networks reveal real biology
Public repositories already hold the answers to many biological questions. The challenge is turning expression data into biology. This article explains how co-expression networks built across many independent studies reveal how genes work together, and how they turn a long list of differentially expressed genes into a few biological programs you can interpret.
· Mavatar R&D team
Unlocking Discovery in Rare & Complex Diseases
Rare diseases have few patients and little data to study. This article shows four ways to work around that in Mavatar Discovery: starting from known disease genes, learning from how existing treatments work, looking across affected tissues, and finding biology shared with related conditions.